Peter Lynch fit · Growth at a reasonable price (GARP)
Is Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) a Peter Lynch Stock?
Strong GARP candidate — growth at a reasonable price.
72/100
BProbable acción Lynch
5/6 criterios cumplidos
Los criterios de Peter Lynch, aplicados a AMRX
PEG ≤ 1.0
clave—
EPS CAGR ≥ 15%
clave37.4%
Revenue CAGR ≥ 10%
37.6%
Net margin > 0
0.2%
Cómo se valora AMRX en otras estrategias
Datos financieros en vivo
Cap. mercado
$4.21B
PER (TTM)
-
ROIC (TTM)
9.19%
Margen bruto
36.76%
Preguntas frecuentes
What is AMRX's Peter Lynch fit score?
AMRX scores 72/100 on our Peter Lynch fit engine — grade B. Strong GARP candidate — growth at a reasonable price.
Does Peter Lynch actually own AMRX?
Our score is computed from financial fundamentals against Peter Lynch's published criteria. We don't claim that Peter Lynch personally owns or recommends AMRX.
How often is this score updated?
AMRX's Peter Lynch fit score is recomputed daily from the latest TTM financials.
Herramienta educativa, no es asesoramiento financiero. Las puntuaciones se calculan a partir de datos financieros públicos contra los criterios publicados de cada estrategia de inversión. No afirmamos que Peter Lynch posea o recomiende AMRX personalmente.